BB Biotech should be able to report a significant increase in NAV tomorrow as a result of a positive trial outcome – with a corresponding c.25%increase in share price – by one of its largest holdings, the US-listed, Belgian company Argenx. The news represents an important fillip for the Swiss investment company, which has seen […]
Biotechnology is an exciting and potentially rewarding sector for investment but for the private investor it is also risky and probably best addressed through collective investment vehicles. After all, development of new drugs is hugely expensive (and thus funding-dependent), scientifically uncertain and fraught with operational challenges and pitfalls. And adding to this is the fact […]
Switzerland’s BB Biotech has opened a new investment position in Rivus Pharmaceuticals, a privately held US biotech developing a mitochondrial-based approach to obesity and cardio-metabolic disease. This was made as part of a $132m Series B financing that is notable for its size and the top-tier syndicate of healthcare specialist investors who have participated. The […]
BB Biotech shares closed yesterday at CHF 57 per share, down 26.5% in the year-to-date period, but crucially up by 12% since mid-June when the shares hit a recent nadir of CHF51 per share. NAV, at CHF49.95 per share, is down by 9.95% year-to-date (YTD), but has gained 22% from its recent nadir of CHF40.9 […]
With valuations in biotech having fallen substantially in the last year, BB Biotech (SWX: BION) sees compelling opportunities in the small-to-mid cap space this year and believes some of its core portfolio companies, such as Neurocrine, Incyte and Ionis Pharmaceuticals, could see interest from strategic investors, including as M&A targets. The comments come in the […]
BB Biotech (SWX: BION) seems to be resilient in the current challenging period for biotech investing and most especially in the last week, which ranks as one of the most important trading periods in the biotech calendar. The Swiss investment company saw a 0.8% fall in its NAV in the five days from January 10-14th […]
Swiss investment company BB Biotech (SWX:BION) closed 2021 with its shares trading at CHF77.15, a rise by 8.3% over the year. However, the positive stock performance contrasts with an 11.4% fall in its NAV to CHF59.4/share in 2021, which was adversely affected by the severe bear market for biotech – and particularly its small to […]
BB Biotech has disclosed an increase in its holding in Mersana Therapeutics (Nasdaq:NRSN), the timing of which suggests it again aims to capitalise on a 40% fall in an investee company’s share price that occurred after a clinical trial update earlier in the month. The Swiss investment company disclosed the increased holding in a SEC […]
Swiss investor BB Biotech’s (SWX:BION) large position in US covid vaccine producer Moderna continues to drive a remarkable performance in a volatile US biotech market. Yesterday, Moderna (Nasdaq: MRNA) surged 17% to a new all-time high of $484.5/share, giving it a market capitalisation of $167bn. Moderna is the largest of BB Biotech’s holdings accounting for […]
Essa Pharmaceutials (Nasdaq: EPIX) and Moderna (MRNA) may have been the top performers within Swiss investment company BB Biotech’s (SIX:BION) 34-strong portfolio in the first half, sporting stock price rises of 137% and 124% respectively, but these gains are modest by comparison with some of the ones from within the wider world of biotech investing. […]
